{"entity":{"id":"sti-3258","kind":"drug","name":"STI-3258","aka":[],"tldr":"The first registered STI-3258 TROP-2 study was withdrawn before enrolling any participants.","summary":"NCT05060276 describes an anti-TROP2 antibody-drug conjugate phase 1 study, withdrawn with zero actual participants because the protocol changed to phase 2. Withdrawal of this study is not evidence of clinical inefficacy or proof that the entire asset was abandoned.","status":"historic","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT05060276","url":"https://clinicaltrials.gov/study/NCT05060276"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["trop2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05060276"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"Antibody-drug conjugate","mechanism":"Anti-TROP2 antibody-drug conjugate described in NCT05060276.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/sti-3258/","neighbours":{"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"trial":[{"id":"nct05060276","kind":"trial","name":"Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors","route":"/trials/nct05060276/"}]}}